Treatment

Updated December 2019.

This section of the Psoriasis Learning Zone reviews the established topical, systemic and biologic treatments available for psoriasis, considering their mode of action, available clinical data and place in the therapeutic pathway. These include the tumour necrosis factor-α (TNFα) and interleukin (IL) antagonists currently available and under development.

Overview

Overview

Until recently, treatment for psoriasis was aimed at managing acute symptoms. Now long-term systemic maintenance therapy is recognised as the preferred method of clinical management.

Psoriasis management

Psoriasis management

This section covers the multidisciplinary, comprehensive, patient-centred management approach recommended for psoriasis patients, as well as current unmet needs.

Topical treatments

Topical treatments

Topical treatments can be used as first-line therapy in psoriasis, defined as <10% of body surface area affected.

Systemic treatments

Systemic treatments

A range of traditional systemic treatment has been used for the management of psoriasis for several years, however, a novel systemic therapy recently entered the psoriasis armamentarium.

Approved biologic treatments

Approved biologic treatments

Biologic treatments for psoriasis have become well established as second-line treatments. They include both TNFα inhibitors and interleukin-based therapies.

Biosimilars

Biosimilars

The patents for many of the biologics currently used to treat psoriasis will expire over the next few years, opening the door for biosimilars. Find out more here.

Biologic treatments in development

Biologic treatments in development

Find out about the treatments currently under investigation.

Login/ Register Maximise Minimise